Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease
NCT07063823Phase 1Completed
- Sponsor
- Nielsen Fernandez-Becker
- Start
- Aug 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HB-2121 in celiac disease (6 arms), sponsored by Nielsen Fernandez-Becker. Primary endpoint: Adverse Events at 30 days. Started Aug 2025; status: completed.
02
Drugs
HB-2121
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT07063823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07063823.